Omeros Burns Cash While Everyone Waits for YARTEMLEA's Story

Omeros Corporation (NASDAQ: OMER) reports fourth quarter and full-year 2025 results after market close on March 31, 2026, with a conference call scheduled for 4:30 p.m. Eastern Time. The commercial-stage biotechnology company faces investor scrutiny over the trajectory of its FDA-approved lectin pathway inhibitor YARTEMLEA and the financial impact of its recent asset sale to Novo Nordisk. With the stock trading at $9.81 and analysts maintaining a consensus buy rating with a $43.67 price target, the report will test whether management can demonstrate a path to profitability following strategic portfolio reshaping.

Part 1: Earnings Preview

Omeros Corporation is a commercial-stage biotechnology company focused on complement-mediated diseases, cancers, and addictive disorders, with its lead product YARTEMLEA (narsoplimab-wuug) FDA-approved for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The company recently sold global rights to zaltenibart to Novo Nordisk while advancing its pipeline including OMS1029, a long-acting MASP-2 inhibitor, and OMS527 for cocaine use disorder.

For the fourth quarter ending December 31, 2025, analysts expect a loss of $0.55 per share on zero revenue. The company most recently reported a loss of $0.19 per share for Q3 2025, significantly beating the $0.58 consensus estimate by 67.24%. Year-over-year, the Q4 estimate represents a 12.70% improvement from the $0.63 loss reported in Q4 2024.

Three key themes define this earnings story:

YARTEMLEA Commercial Traction: Investors will scrutinize revenue generation from the FDA-approved TA-TMA treatment and progress on the European marketing authorization application currently under review at the European Medicines Agency. Commercial execution remains critical as the company transitions from development to revenue-generating operations.

Novo Nordisk Transaction Impact: The recently announced asset purchase and licensing agreement for zaltenibart represents a significant portfolio reshaping. Investors will seek clarity on the financial terms, upfront payments, milestone structure, and how proceeds will be deployed across the remaining pipeline and operations.

Pipeline Advancement and Cash Runway: With OMS1029 completing Phase 1 trials and OMS527 fully funded by the National Institute on Drug Abuse, management must articulate development timelines and capital requirements. The company's ability to extend its cash runway while advancing multiple programs will be central to investor confidence.

Analyst commentary ahead of the release reflects cautious optimism, with three strong buy ratings and three hold ratings among the six covering analysts. The consensus maintains a buy-equivalent rating of 4.00, unchanged from a month ago, suggesting stable conviction despite recent stock weakness. The $43.67 average price target implies substantial upside, though analysts will be watching for updated guidance on commercial ramp expectations and the strategic rationale behind the Novo Nordisk deal.

Part 2: Historical Earnings Performance

Omeros has demonstrated a pattern of beating analyst expectations in recent quarters, though the magnitude varies considerably. In Q3 2025, the company delivered its strongest performance with a reported loss of $0.53 versus the $0.55 estimate, representing a 3.64% beat, followed by an even more impressive Q3 result of $0.19 against a $0.58 estimate—a 67.24% outperformance that significantly exceeded expectations.

The year-over-year trend shows meaningful improvement in the company's loss profile. Comparing sequential quarters, losses have narrowed from $0.65 in Q1 2025 to $0.19 in Q3 2025, suggesting operational progress. However, the lack of estimates for Q4 2024 and Q1 2025 limits visibility into whether these beats reflect conservative analyst modeling or genuine operational outperformance. The upcoming Q4 2025 report will be critical in determining whether the Q3 momentum represents a sustainable inflection point or a one-time benefit from specific events like the Novo Nordisk transaction.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Omeros typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price behavior around Omeros earnings reveals extreme volatility with an average absolute Day +1 move of 18.93% and an average Day +1 range of 23.27%. The most dramatic reaction occurred following the November 2024 report, when shares surged 65.87% on Day +1 with a 73.99% intraday range, demonstrating the stock's capacity for explosive moves on positive surprises.

More recently, the pattern has been mixed. The November 2025 report triggered an 8.85% decline on Day 0 followed by a 25.32% Day +1 rally, while the May 2025 report saw minimal Day 0 movement but an 18.61% Day +1 decline. The average Day 0 move of 3.84% is relatively modest compared to the Day +1 average, consistent with after-hours reporting where initial reactions are muted. Investors should prepare for significant volatility, with historical data suggesting moves exceeding 15-20% are common in either direction depending on the magnitude of any earnings surprise and guidance commentary.

Part 2.2: Options Market Expected Move

The options market is pricing a 14.47% expected move through the April 17 expiration, implying a range between $8.39 and $11.23. This expected move is notably lower than the stock's average historical Day +1 move of 18.93%, suggesting options traders may be underpricing potential volatility or that recent extreme moves are viewed as outliers rather than the baseline expectation.

Part 3: What Analysts Are Saying

Analysts maintain a constructive stance on Omeros with a consensus rating of 4.00 (Buy) and an average price target of $43.67, implying 345% upside from the current $9.81 price. The rating breakdown shows 3 strong buy recommendations and 3 hold ratings, with no sell-side calls, reflecting confidence in the company's long-term potential despite near-term execution risks.

Sentiment has remained unchanged over the past month, with the 4.00 average recommendation holding steady and the total analyst count stable at six. The price target range spans from $36.00 to $55.00, with the high-end estimate suggesting particularly bullish conviction among some analysts. This wide range reflects differing views on the commercial trajectory of YARTEMLEA and the value creation potential from the pipeline.

The substantial implied upside from the consensus target indicates analysts see the current valuation as disconnected from the company's fundamental prospects. However, the presence of three hold ratings alongside three strong buys suggests some caution about near-term catalysts, likely tied to questions about commercial execution, cash burn, and the timing of pipeline milestones. The unchanged sentiment despite recent stock weakness suggests analysts are looking through short-term volatility to longer-term value creation opportunities.

Part 4: Technical Picture

The Barchart Technical Opinion currently registers a 16% Buy signal, representing a significant deterioration from the 24% Buy reading one week ago and the 56% Buy signal from one month ago. This weakening technical picture reflects mounting selling pressure as the stock approaches earnings.

Timeframe Analysis:

• Short-term (25% Sell): Bearish signal indicates near-term momentum has turned negative heading into the report
• Medium-term (50% Buy): Moderate buy signal suggests the intermediate trend remains constructive despite recent weakness
• Long-term (50% Buy): Moderate buy signal reflects positive longer-term trend structure above key support levels

Trend Characteristics: The trend is characterized as Weak and Weakening, indicating deteriorating momentum and fragile technical support as earnings approach.

At $9.81, OMER trades below all short- and intermediate-term moving averages—below the 5-day ($10.12), 10-day ($10.56), 20-day ($11.03), 50-day ($11.44), and 100-day ($11.03)—but remains above the 200-day moving average at $7.76, which represents critical long-term support. The stock has declined 14.3% during the current quarter, establishing a downtrend that places additional pressure on the earnings report to deliver positive surprises. The technical setup is cautionary, with multiple resistance levels overhead and weakening momentum suggesting the stock needs a strong fundamental catalyst to reverse the recent selling pressure. The 200-day moving average at $7.76 represents the key level to watch—a break below would signal broader technical deterioration, while a strong earnings reaction could target reclaiming the 20-day average near $11.00.